The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

• Published in: Clinical chemistry (Baltimore, Md.) Md.), 1998-10, Vol.44 (10), p.2115-2119
• Main Authors: Saedi, Mohammad S, Hill, Timothy M, Kuus-Reichel, Kristine, Kumar, Abhay, Payne, Janice, Mikolajczyk, Stephen D, Wolfert, Robert L, Rittenhouse, Harry G
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - immunology; Biological and medical sciences; Biomarkers, Tumor - blood; Blotting, Western; Humans; Immunoassay; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Prekallikrein - analysis; Prekallikrein - biosynthesis; Prekallikrein - immunology; Prostate-Specific Antigen - blood; Prostatic Hyperplasia - blood; Prostatic Hyperplasia - metabolism; Prostatic Neoplasms - blood; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Sensitivity and Specificity; Tumor Cells, Cultured; Urinary system
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/44.10.2115

Prostate-specific antigen (PSA, hK3) is a diagnostic marker for prostatic cancer but lacks the specificity to sufficiently distinguish between prostatic cancer and benign prostatic hyperplasia (BPH). Human glandular kallikrein 2 (hK2) has been proposed as a potential diagnostic marker for prostate cancer that could complement the current PSA test. Recently we demonstrated that proPSA is present in prostate cancer sera. This study examines the expression of prohK2 in prostate cells and its presence in human sera. Western blot analysis was used to assess prohK2 expression in the human carcinoma cell line, LNCaP. A highly specific and sensitive dual monoclonal immunoassay for prohK2 was developed and used to assess the presence of prohK2 in human sera. prohK2 was detected in the spent media of LNCaP cells. Furthermore, prohK2 was present at immunodetectable concentrations in human sera, and its concentration was increased in prostatic cancer and BPH. These results indicate for the first time that prohK2 is secreted by human prostate cells and is a major component of uncomplexed (free) hK2 in human sera. In addition, prohK2 in human sera is associated with prostate disease and thus may be a useful marker for prostatic cancer and BPH.